Last edition
News about
Lupin Secures US FDA Approval for Pegfilgrastim Biosimilar Armlupeg
Lupin has received approval from the U.S. Food and Drug Administration (FDA) for its biosimilar Armlupeg (pegfilgrastim-unne), marking an important milestone in the company’s biologics journey. Armlupeg is a biosimilar to Neulasta (pegfilgrastim), a widely used therapy that helps reduce infection risk in cancer patients undergoing chemotherapy.
Sun Pharma Introduces ILUMYA in India for Plaque Psoriasis Treatment
Sun Pharma has launched its global innovative drug, ILUMYA (Tildrakizumab), in India for the treatment of moderate-to-severe plaque psoriasis.
Ascletis Advances First Oral Triple Agonist ASC37 to Clinical Development
Ascletis has selected ASC37—its first oral GLP-1R/GIPR/GCGR triple peptide agonist—for clinical development. Using the company’s POTENT technology, ASC37 showed markedly higher oral bioavailability and drug exposure than leading agents in non-human primate studies.
Fischer Medical Ventures (FMV), through its wholly owned subsidiary Time Medical International Ventures India, has entered into a strategic partnership with Indonesia, in collaboration with PT Pharmindo Rimpang Kokoh (PT Pariko), to support the country’s tuberculosis eradication efforts with advanced portable, AI-enabled X-ray systems.
Lung Cancer Canada and Boehringer Ingelheim Canada Partner to Advance NSCLC Diagnostics
Lung Cancer Canada and Boehringer Ingelheim have launched a two-stage initiative to accelerate innovation in NSCLC diagnostics. The effort begins with a national Diagnostic Innovation Lab to identify key barriers in diagnosis, followed by an innovation challenge seeking solutions to close those gaps.
Novo Nordisk Files for FDA Approval of Wegovy Injection 7.2 mg
Novo Nordisk has filed an sNDA with the US FDA for a 7.2 mg dose of Wegovy, aiming to offer a higher-dose option for adults with obesity. The application, supported by STEP UP trial data showing 20.7 percent average weight loss, will be reviewed under the FDA’s expedited CNPV pathway.
New Innovation Hub to Make Maharashtra a Global Pharma & Biotech Hub
The government of Maharashtra plans to establish a state-of-the-art Life Sciences Innovation and Incubation Centre aimed at boosting research and development in pharmaceuticals, biotechnology, medical devices, diagnostics and digital health.
SK Biopharmaceuticals Expands Radiopharma Portfolio with New WARF In-Licensing
SK Biopharmaceuticals has in-licensed a second radiopharmaceutical therapy candidate from the Wisconsin Alumni Research Foundation (WARF), further strengthening its pipeline and advancing its strategy to build an integrated, globally competitive radiotherapeutics portfolio.
US FDA Classifies Biocon Biologics' Bengaluru Drug Substance Facility as VAI
The US FDA has classified Biocon Biologics’ Bengaluru drug substance facility as Voluntary Action Indicated (VAI) following an inspection in August–September 2025. The review covers the site’s production of rh-Insulin and biosimilar Pegfilgrastim for the US market.
Cipla Launches India's First Dedicated Lung Health Diagnostics Centre in Delhi
Cipla has opened the country’s first dedicated lung diagnostics centre in Delhi, equipped to conduct over 60 tests across respiratory function, microbial studies, immune profiling, blood chemistry and imaging.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy